Chemical: Drug
practolol

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Generic Names
  • Tocris-0831
Trade Names
Brand Mixture Names

PharmGKB Accession Id

PA164752820

Type(s):

Drug

Description

A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.

Source: Drug Bank

Indication

Used in the emergency treatment of cardiac arrhythmias.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Like other beta-adrenergic antagonists, practolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, practolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure.

Source: Drug Bank

Pharmacology

Practolol is a beta-adrenergic receptor antagonist that has been used in the emergency treatment of cardiac arrhythmias. Beta blockers inhibit normal epinephrine-mediated sympathetic actions, but have minimal effect on resting subjects. That is, they reduce the effect of excitement/physical exertion on heart rate and force of contraction and dilation of blood vessels.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Avoid natural licorice.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Toxicity

Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.

Source: Drug Bank

Chemical Properties

Chemical Formula

C14H22N2O3

Source: Drug Bank

Isomeric SMILES

CC(C)NCC(COc1ccc(cc1)NC(=O)C)O

Source: OpenEye

Canonical SMILES

CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1

Source: Drug Bank

Average Molecular Weight

266.3361

Source: Drug Bank

Monoisotopic Molecular Weight

266.16304258

Source: Drug Bank

SMILES

CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1

Source: Drug Bank

InChI String

InChI=1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Drug Targets

Gene Description
ADRB1 (source: Drug Bank)

Drug Interactions

Interaction Description
acetohexamide - practolol The beta-blocker, practolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
chlorpropamide - practolol The beta-blocker, practolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
clonidine - practolol Increased hypertension when clonidine stopped (source: Drug Bank)
clonidine - practolol Increased hypertension when clonidine stopped (source: Drug Bank)
dihydroergotamine - practolol Ischemia with risk of gangrene (source: Drug Bank)
dihydroergotamine - practolol Ischemia with risk of gangrene (source: Drug Bank)
disopyramide - practolol The beta-blocker, practolol, may increase the toxicity of disopyramide. (source: Drug Bank)
epinephrine - practolol Hypertension, then bradycardia (source: Drug Bank)
epinephrine - practolol Hypertension, then bradycardia (source: Drug Bank)
ergotamine - practolol Ischemia with risk of gangrene (source: Drug Bank)
ergotamine - practolol Ischemia with risk of gangrene (source: Drug Bank)
fenoterol - practolol Antagonism (source: Drug Bank)
fenoterol - practolol Antagonism (source: Drug Bank)
formoterol - practolol Antagonism (source: Drug Bank)
glibenclamide - practolol The beta-blocker decreases the symptoms of hypoglycemia (source: Drug Bank)
glibenclamide - practolol The beta-blocker, practolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
gliclazide - practolol The beta-blocker, practolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
ibuprofen - practolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin - practolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
indomethacin - practolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
insulin-glargine - practolol The beta-blocker, practolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
insulin-glargine - practolol The beta-blocker, practolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
methysergide - practolol Ischemia with risk of gangrene (source: Drug Bank)
methysergide - practolol Ischemia with risk of gangrene (source: Drug Bank)
orciprenaline - practolol Antagonism (source: Drug Bank)
oxprenolol - practolol Antagonism (source: Drug Bank)
pipobroman - practolol Antagonism (source: Drug Bank)
piroxicam - practolol Risk of inhibition of renal prostaglandins (source: Drug Bank)
prazosin - practolol Risk of hypotension at the beginning of therapy (source: Drug Bank)
prazosin - practolol Risk of hypotension at the beginning of therapy (source: Drug Bank)
repaglinide - practolol The beta-blocker, practolol, may decrease symptoms of hypoglycemia. (source: Drug Bank)
terbutaline - practolol Antagonism (source: Drug Bank)
terbutaline - practolol Antagonism (source: Drug Bank)
No related diseases are available

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB01297
ChEBI:
258351
KEGG Compound:
C11696
KEGG Drug:
D05587
PubChem Compound:
443371
PubChem Substance:
10299290
IUPHAR Ligand:
555
Therapeutic Targets Database:
DAP000940

Clinical Trials

These are trials that mention practolol and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.